[go: up one dir, main page]

AR032072A1 - Derivados de quinuclidina novedosos y composiciones medicinales que los contienen - Google Patents

Derivados de quinuclidina novedosos y composiciones medicinales que los contienen

Info

Publication number
AR032072A1
AR032072A1 ARP010106065A ARP010106065A AR032072A1 AR 032072 A1 AR032072 A1 AR 032072A1 AR P010106065 A ARP010106065 A AR P010106065A AR P010106065 A ARP010106065 A AR P010106065A AR 032072 A1 AR032072 A1 AR 032072A1
Authority
AR
Argentina
Prior art keywords
group
straight
hydrogen
carbon atoms
lower alkyl
Prior art date
Application number
ARP010106065A
Other languages
English (en)
Original Assignee
Almirall Prodesfarma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Ag filed Critical Almirall Prodesfarma Ag
Publication of AR032072A1 publication Critical patent/AR032072A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la formula (1), en donde R es un anillo fenilo, un grupo heteroaromático de 5 a 10 miembros que contiene un grupo benzo[1,3]dioxolilo, o bifenilo, R1, R2 y R3 cada uno independientemente representa un átomo de hidrogeno o halogeno, o un grupo hidroxi, un grupo fenilo, -OR7, -SR7, -NR7R8-, grupo alquilo inferior sustituido o sin sustituir, en donde R7 y R8 cada uno independientemente representa un átomo de hidrogeno, un grupo alquilo inferior recto o ramificado, o conjuntamente forman un anillo alicíclico o R1 y R2 conjuntamente forman un anillo aromático o alicíclico o un grupo heterocíclico; n es un entero de 0 a 4; A representa un grupo seleccionado entre -CH2-, CH=CR9-, CR9=CH-, CR9R10-, -CO-, -O-, -S-, -S(O)2 y -NR9-, en donde R9 y R10 cada uno independientemente representa un átomo de hidrogeno, un grupo alquilo recto o ramificado de alquilo inferior, o conjuntamente forman un anillo alicíclico; m es un entero de 0 a 8, siempre que cuando m = 0, A no es -CH2-; p es un entero de 1 a 2 y la sustitucion del anillo bicíclico de azonia puede ser en la posicion 2, 3 o 4 incluyendo todas las configuraciones posibles de los carbonos asimétricos; R4 representa un grupo de estructura (2) en donde R11 representa un átomo de hidrogeno o halogeno, un grupo hidroxi, un grupo alcoxi, un grupo nitro, un grupo ciano, -CO2R12, o NR12R13, en donde R12 y R13 son idénticos o diferentes y son seleccionados entre hidrogeno y grupos de alquilo inferior recto o ramificado, o un grupo alquilo inferior recto o ramificado, sustituido o no sustituido; R5 representa un grupo alquilo de 1 a 7 átomos de carbono, un grupo alquenilo que contiene 2 a 7 átomos de carbono; un grupo alquinilo que contiene 2 a 7 átomos de carbono, un grupo cicloalquilo de 3 a 7 átomos de carbonos, o un grupo de la formula (3), en donde q = 1 o 2 y R11 es tal como se define anteriormente; R6 representa un átomo de hidrogeno, un grupo hidroxi, un grupo metilo, o un grupo CH2OH. El carbono asimétrico en la posicion alfa con respecto al grupo éster, que es sustituido por R4, R5 y R6 puede tener configuracion R o S; X- representa un anion farmacéuticamente aceptable de un ácido mono o polivalente.
ARP010106065A 2000-12-28 2001-12-27 Derivados de quinuclidina novedosos y composiciones medicinales que los contienen AR032072A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200003130 2000-12-28

Publications (1)

Publication Number Publication Date
AR032072A1 true AR032072A1 (es) 2003-10-22

Family

ID=8496180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106065A AR032072A1 (es) 2000-12-28 2001-12-27 Derivados de quinuclidina novedosos y composiciones medicinales que los contienen

Country Status (34)

Country Link
US (4) US7122558B2 (es)
EP (1) EP1353919B1 (es)
JP (1) JP4295985B2 (es)
KR (1) KR100869721B1 (es)
CN (1) CN1250545C (es)
AR (1) AR032072A1 (es)
AT (1) ATE334128T1 (es)
AU (1) AU2002238471B2 (es)
BG (1) BG66162B1 (es)
BR (1) BR0116624A (es)
CA (1) CA2433128C (es)
CY (1) CY1105719T1 (es)
CZ (1) CZ301209B6 (es)
DE (1) DE60121813T2 (es)
DK (1) DK1353919T3 (es)
EC (1) ECSP034672A (es)
EE (1) EE05404B1 (es)
ES (1) ES2266291T3 (es)
HK (1) HK1055739A1 (es)
HU (1) HUP0303524A3 (es)
IL (2) IL156558A0 (es)
MX (1) MXPA03005862A (es)
MY (1) MY136067A (es)
NO (1) NO328772B1 (es)
NZ (1) NZ526674A (es)
PE (1) PE20020721A1 (es)
PL (1) PL363807A1 (es)
PT (1) PT1353919E (es)
RU (1) RU2282629C2 (es)
SI (1) SI1353919T1 (es)
SK (1) SK287414B6 (es)
UA (1) UA75626C2 (es)
WO (1) WO2002053564A2 (es)
ZA (1) ZA200305008B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) * 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
ATE419236T1 (de) 2002-07-08 2009-01-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
EP1545508A4 (en) * 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) * 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
JP4616264B2 (ja) 2003-05-28 2011-01-19 セラヴァンス, インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
EP1644356A1 (en) 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1891974B1 (en) * 2004-05-31 2010-07-21 Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0617674A2 (pt) 2005-10-19 2011-08-02 Ranbaxy Lab Ltd composições farmacêuticas e seus usos
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP5293192B2 (ja) 2007-02-09 2013-09-18 アステラス製薬株式会社 アザ架橋環化合物
MX2009008323A (es) * 2007-02-15 2009-08-13 Argenta Discovery Ltd Derivados heterociclicos como receptores muscarinicos m3.
ATE499363T1 (de) 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
BRPI0816219B8 (pt) 2007-09-07 2021-05-25 Theravance Biopharma R&D Ip Llc compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
EP2222637A1 (en) 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
CA2945069A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Cf、copd、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465834A (en) * 1965-09-20 1984-08-14 Fmc Corporation Anticholinergic drugs
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US4082756A (en) * 1971-04-16 1978-04-04 Colgate-Palmolive Company Quaternary quinuclidinium carbamates and thiocarbamates
JPS57500735A (es) * 1980-06-03 1982-04-30
US4431627A (en) * 1980-06-03 1984-02-14 Research Corporation Gamma-emitting receptor-binding 3-quinuclidinyl glycolates; methods of preparation thereof and imaging and assay methods utilizing same
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
IL72788A (en) * 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
JPH0725756B2 (ja) 1990-09-06 1995-03-22 ファイザー・インコーポレーテッド 抗ムスカリン性気管支拡張剤
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
EP0863141B1 (en) * 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
AU2002228015B2 (en) * 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) * 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same

Also Published As

Publication number Publication date
AU2002238471B2 (en) 2007-06-28
PE20020721A1 (es) 2002-10-01
IL156558A0 (en) 2004-01-04
US20100234332A1 (en) 2010-09-16
RU2003123120A (ru) 2005-01-10
WO2002053564A2 (en) 2002-07-11
PT1353919E (pt) 2006-11-30
US7122558B2 (en) 2006-10-17
US20040072863A1 (en) 2004-04-15
BG66162B1 (bg) 2011-09-30
CA2433128A1 (en) 2002-07-11
US7893087B2 (en) 2011-02-22
EP1353919B1 (en) 2006-07-26
UA75626C2 (en) 2006-05-15
JP2004517123A (ja) 2004-06-10
HK1055739A1 (en) 2004-01-21
CN1487938A (zh) 2004-04-07
BR0116624A (pt) 2003-12-23
CY1105719T1 (el) 2010-12-22
CZ20031812A3 (en) 2004-05-12
NZ526674A (en) 2005-03-24
EE200300312A (et) 2003-10-15
PL363807A1 (en) 2004-11-29
ES2266291T3 (es) 2007-03-01
IL156558A (en) 2009-06-15
NO328772B1 (no) 2010-05-10
KR20030067726A (ko) 2003-08-14
MY136067A (en) 2008-08-29
SK7992003A3 (en) 2004-08-03
CA2433128C (en) 2010-05-25
WO2002053564A3 (en) 2002-10-31
EP1353919A2 (en) 2003-10-22
ATE334128T1 (de) 2006-08-15
NO20033002D0 (no) 2003-06-30
DE60121813D1 (de) 2006-09-07
RU2282629C2 (ru) 2006-08-27
US20070105897A1 (en) 2007-05-10
NO20033002L (no) 2003-06-30
EE05404B1 (et) 2011-04-15
JP4295985B2 (ja) 2009-07-15
CZ301209B6 (cs) 2009-12-09
SI1353919T1 (sl) 2006-12-31
HUP0303524A2 (hu) 2004-01-28
CN1250545C (zh) 2006-04-12
MXPA03005862A (es) 2005-09-08
HUP0303524A3 (en) 2008-03-28
BG107950A (bg) 2004-03-31
DE60121813T2 (de) 2007-09-20
ECSP034672A (es) 2003-08-29
US7879874B2 (en) 2011-02-01
DK1353919T3 (da) 2006-11-20
US20070129398A1 (en) 2007-06-07
SK287414B6 (sk) 2010-09-07
KR100869721B1 (ko) 2008-11-21
ZA200305008B (en) 2005-01-26

Similar Documents

Publication Publication Date Title
AR032072A1 (es) Derivados de quinuclidina novedosos y composiciones medicinales que los contienen
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
CO5060482A1 (es) Derivados terapeuticos de biarilo
AR054090A1 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
KR910020009A (ko) 비사이클릭 1-아자-사이클로알칸
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
BR0307268A (pt) Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
HUP0402508A2 (hu) 1,2,3,4-Tetrahidro-izokinolin-származékok mint urotenzin II receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
AR059076A1 (es) Tiofenil y pirrolil azepinas como ligandos del receptor 5-ht2c de serotonina y usos de las mismas
BR0013498A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation

Legal Events

Date Code Title Description
FB Suspension of granting procedure